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Abstract
Background: Highly effective antiviral treatment can suppress HIV-1 infection, but the chronic effects of HIV-1-
related viral proteins, including gp120 and Tat, on organs such as the lungs can be damaging. HIV-1 transgenic
rodent models are useful for studying the systemic effects of these proteins independently of viral infection. We
have previously shown that HIV-1 transgene expression (and therefore, HIV-1-related protein expression) in rats
decreases alveolar macrophage zinc levels and phagocytic capacity by unknown mechanisms. We hypothesized
that HIV-1 transgene expression induces chronic inflammation and zinc sequestration within the liver and thereby
decreases zinc bioavailability in the lung. We examined the expression of the pro-inflammatory cytokine, tumor
necrosis factor alpha (TNFa), the zinc storage protein, metallothionein (MT1), and the zinc exporter, ZNT1 in the
livers and the lungs of wild type and HIV-1 transgenic rats ± dietary zinc supplementation. In addition, we
measured zinc levels, the zinc importing protein ZIP1, and the phagocytic capacity in the alveolar macrophages.
Results: HIV-1 transgene expression increased the liver-specific expression of TNFa, suggesting a chronic
inflammatory response within the liver in response to HIV-1-related protein expression. In parallel, HIV-1 transgene
expression significantly increased MT1 and ZNT1 expression in the liver as compared to the lung, a pattern that is
consistent with zinc sequestration in the liver as occurs during systemic inflammation. Further, HIV-1 transgene
expression decreased intracellular zinc levels and increased expression of ZIP1 in the alveolar macrophages, a
pattern consistent with zinc deficiency, and decreased their bacterial phagocytic capacity. Interestingly, dietary zinc
supplementation in HIV-1 transgenic rats decreased gene expression of TNFa, MT1, and ZNT1 in the liver while
simultaneously increasing their expression in the lung. In parallel, zinc supplementation increased alveolar
macrophage intracellular zinc levels and bacterial phagocytic capacity in HIV-1 transgenic rats.
Conclusion: Taken together, these findings suggest that chronic HIV-1-related protein expression causes liver
inflammation and zinc sequestration, which in turn limits zinc bioavailability in the lung and thereby impairs
alveolar macrophage phagocytic function. Importantly, dietary zinc supplementation decreases liver inflammation
and zinc sequestration and restores alveolar macrophage phagocytic function in HIV-1 transgenic rats, a result with
potential clinical implications for improving lung health in HIV-1-infected individuals.
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Despite significant advances in HIV-1 treatment including
the development of highly active anti-retroviral therapy
(HAART), infected individuals are prone to pneumonias
by multiple pathogens including Klebsiella pneumoniae
and Mycobacterium tuberculosis [1,2]. In addition, HIV-1-
infected individuals are at increased risk for more typical
community-acquired pneumonias from Pneumococcal
pneumoniae and influenza [3,4]. Although the precise
mechanisms are being investigated, HIV-1 can infect
alveolar macrophages [5], and there is considerable evi-
dence that phagocytosis and other innate immune func-
tions are impaired in monocytes/macrophages from HIV-
1 infected individuals [6,7]. For example, in immunocom-
petent individuals Klebsiella pneumoniae usually produces
a mild respiratory illness. However, in alcoholics and in
HIV-1-infected individuals, Klebsiella evades the normal
innate immune defenses within the lower airways and can
produce an overwhelming and frequently fatal pneumonia.
In experimental models, HIV-1 infection decreases phago-
cytosis and increases the severity of lung infection from
diverse organisms including Streptococcus pneumoniae,
Klebsiella pneumoniae, Mycobacterium tuberculosis,a n d
Pneumocystis carinii [1,2,6]. These observations raise the
novel possibility that unrecognized macrophage dysfunc-
tion in HIV-1-infected individuals could contribute to the
morbidity and mortality of lung infections in these vulner-
able patients. Therefore, it is important to identify the
mechanisms by which alveolar macrophage immune func-
tion is compromised in chronic HIV-1 infection so that
new complementary therapies aimed at improving pul-
monary host defenses can be developed.
D i e t a r yz i n cd e f i c i e n c yi sc o m m o ng l o b a l l ya n d
appears to contribute to the pathogenesis of many dis-
eases [8,9]. Besides dietary deficiency, low zinc levels are
present in individuals with other abnormalities that
either limit zinc absorption, such as in alcoholics, or
that cause hepatic zinc sequestration, such as infections.
While HIV-1 infection has a strong association with
zinc deficiency, the exact mechanisms are not known.
Zinc deficiency produces numerous abnormalities, but is
particularly detrimental to epithelial cells and the
immune system [9-11]. A higher incidence of bacterial
infections was reported in HIV-1- infected persons with
low zinc levels [12], and lower levels of zinc correlated
with more advanced stages of the disease [13,14].
Transgenic models are useful to study the impact of
HIV-1-related viral proteins and their roles in the
pathogenesis of AIDS in tissues that are not directly
infected with HIV-1 [15-17]. While such models have
limitations [18], they have yielded significant insights
into many aspects of HIV-1 pathogenesis. Transgenic
mouse models have been instrumental in elucidating
potential mechanisms underlying AIDS nephropathy [19]
and cardiomyopathy [20]. Reid and colleagues established
HIV-1 transgenic rat model in which affected animals are
hemizygous for a NL4-3Δ gag/pol transgene [21]. As a
consequence of expressing HIV-1 proteins such as
gp120, Nef, Tat, and Rev, these transgenic rodents
develop muscle wasting, cataracts, nephropathy, skin
lesions and immune deficiencies that are remarkably
similar to the manifestations of AIDS in humans [21,22].
We recently reported that these HIV-1 transgenic rats
have circulating levels of gp120, and that the alveolar
zinc concentrations decrease with age [23]. The expres-
sion of granulocyte-macrophage colony stimulating fac-
tor (GM-CSF) receptors on alveolar macrophages from
HIV-1 transgenic rats was also significantly decreased
[23], and was associated with impaired macrophage pha-
gocytic function. Interestingly, treating alveolar macro-
phages from HIV-1 transgenic rats with zinc acetate in
vitro improved their bacterial phagocytic function [23].
However, in that study we did not examine the potential
mechanism(s) by which HIV-related protein expression
decreases zinc bioavailability within the lung.
Organ interactions, including liver-lung interactions,
modulate inflammatory and immune responses during
illness [24]. In particular, there is evidence that during
inflammation the liver sequesters zinc, perhaps as an
adaptive response to limit zinc bioavailability to patho-
genic microbes [25,26]. However, if inflammation per-
sists and hepatic zinc sequestration continues, zinc
bioavailability to other tissues such as the lung could be
compromised. Therefore, we hypothesized that the zinc
deficiency and consequent epithelial and macrophage
dysfunction we previously identified in the lungs of
HIV-1 transgenic rats [23,27] might be caused, at least
in part, by chronic liver inflammation and consequent
changes in zinc storage proteins that mediate zinc
sequestration in the liver. To test this hypothesis, we
compared the relative expression of the stereotypical
pro-inflammatory cytokine, tumor necrosis factor a
(TNFa), in the livers and in the lungs of HIV-1 trans-
genic rats and in their wild type littermates. In parallel,
we compared the relative expression of key zinc storage
and transport proteins in the livers and in the lungs of
these animals. Finally, we determined the effects of diet-
ary zinc supplementation on liver inflammation and on
alveolar macrophage zinc bioavailability and bacterial
phagocytic function, with the rationale that such a strat-
egy could be used to improve lung health in individuals
infected with HIV-1.
Materials and methods
HIV-1 transgenic rats
Age-matched HIV-1 transgenic or wild type male
Fischer 344 rats were either purchased from Harlan
Laboratories or produced by a breeding colony we
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engineered to contain the entire genome of the HIV-1
v i r u se x c e p tt h a tt h e3 ’ region of gag and the 5’ region
of pol are deleted [23]. These transgenic rats are born
with cataracts and can be clearly distinguished from
wild type littermates by this phenotype and by tail-snip
DNA analysis. All the work was performed under the
approval of the Institutional Animal Care and Use Com-
mittee at the Atlanta VA Medical Center. In most
experiments, we used transgenic and gender-matched
wild type littermates between the ages of 8-9 months.
Zinc acetate (100 mg/L) was added to the liquid diets of
some rats for 8 weeks prior to sacrifice.
RNA isolation and real-time PCR
Total RNA was extracted using Qiagen RNeasy Mini Kit
(Valencia, CA) and reverse transcription was performed
with Bio-Rad iScript cDNA synthesis kit (Hercules, CA).
Real-time PCR was carried on the Bio-Rad iCycler.
Amplification was performed in Bio-Rad iQ SYBR green
supermix containing specific primers and with denatur-
ing at 95
°C for 20s, annealing at 58
°C for 20s, and exten-
sion at 72
°C for 20s. Standards and samples were run in
triplicate. The primers were designed in our laboratory
and were obtained from Invitrogen (Carlsbad, CA).
QuantumRNA class II 18S primers were purchased from
Ambion (Austin, TX). PCR amplicons from all species
were normalized for the amount of 18S in the same
cDNA sample. Real time SYBR green dissociation curves
showed one species of amplicon for each primer set.
Bronchoalveolar lavage and isolation of alveolar
macrophages
Following pentobarbital anesthesia (100 mg/kg IP), a
tracheotomy tube was placed and rat lungs were lavaged
× 4 with 10 ml of sterile cold PBS (pH 7.4). The recov-
ered lavage solution was centrifuged at 1500 rpm for 7
min, and the cell pellet re-suspended in sterile media
for functional studies. This procedure routinely yields
cells that are >98% viable by trypan blue exclusion test.
Diff-Quick (IMEB, INC) and CD-68 staining is used to
show that >95% cells are alveolar macrophages. For
selected analyses of the effects of zinc depletion on the
expression of zinc transporters in macrophages, we used
the rat alveolar macrophage cell line, NR8383 (ATCC,
Manassas, VA), were maintained in F12K culture media
with 15% fetal bovine serum.
Flow cytometric detection of intracellular zinc
Zinc levels in the freshly isolated alveolar macrophages
were measured using the zinc-specific dye, FluoZin-
3AM (Invitrogen), a recently developed fluorochrome
with a high affinity for zinc (Kd 15 nM). This is a mem-
brane-permeable dye used to detect intracellular zinc.
The alveolar macrophages were stained with this dye for
1 hr at room temperature, and the resulting fluores-
cence was measured using the FACScan Flow Cytometer
(Becton Dickinson). The data are expressed as % posi-
tive cells.
Flow cytometric detection of MT1 expression
The intracellular expression of MT1 in the freshly iso-
lated rat alveolar macrophages was measured by an
established protocol [23]. Briefly, cells were made
permeable with 0.1% saponin in PBS followed by incu-
bation with rabbit anti-MT1 antibody (Santa Cruz Bio-
technology, Santa Cruz, CA) or an isotype-matched
control antibody for 30 minutes at room temperature.
Cells were washed with PBS-saponin before adding
FITC-conjugated donkey anti-rabbit secondary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA). Cells were
washed with PBS and analyzed by FACScan Flow Cyt-
ometer (Becton Dickinson).
Macrophage phagocytosis in vitro
Freshly isolated rat alveolar macrophages were incu-
bated for 1 hour with FITC-conjugated Staphylococcus
aureus (Wood Strain without protein A; Molecular
Probes, Eugene, OR) in a 10:1 ratio. Cells were vigor-
ously washed × 3 with PBS and extracellular fluores-
cence was quenched by adding trypan blue [23]. Cells
with FITC-conjugated bacteria were measured by flow
cytometry. Phagocytic index was calculated as follows:
(% positive cells × mean channel fluorescence)/100.
Statistical analyses
Data are presented as mean ± SEM. Data analysis was
done by one-way ANOVA with Student-Newman-Keuls
test for group comparison, and differences among
groups were considered statistically significant at a p
value of <0.05.
Results
HIV-1 transgenic rats are smaller than their wild type
littermates
Our previous studies have provided new evidence for
the effects of HIV-1- related proteins in the alveolar
space that could have implications for understanding
why HIV-1-infected individuals are prone to pulmonary
infections and respiratory failure [23,27]. Consistent
with the conclusion that not all of the systemic manifes-
tations of AIDS can be attributed directly to viral infec-
tion and replication within target tissues (many of which
cannot be infected by the virus), by the age of 7 months
the HIV-1 transgenic rats begin to display modestly
decreased body weights compared to wild type litter-
mates. By the age of 9 months they are clearly smaller
than their wild type littermates and exhibit systemic
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physical activity (Additional File 1 Figure 1, panels
A&B). By 12 months of age the HIV-1 transgenic rats
show signs of severe disease including hind limb atrophy
and gait difficulties (not shown). These observations are
in agreement with those of Reid and colleagues [21]
who developed this model, and confirm that chronic
HIV-1-related protein expression causes a progressive
systemic phenotype that resembles AIDS in humans.
These findings are consistent with the extensive experi-
mental and clinical evidence that these HIV-1-related
proteins are themselves toxic to a variety of target tis-
sues that are not infected directly by HIV-1.
Increased expression of the pro-inflammatory cytokine
TNFa in the livers of HIV-1 transgenic rats suggests a
chronic inflammatory response
During the acute phase reaction associated with infec-
tions, there is typically an increase in pro-inflammatory
cytokine expression in the liver. As shown in Figure 1
(panel A), gene expression of TNFa in the liver, but not
in the lung, is highly up-regulated in HIV-1 transgenic
rats, suggesting a chronic inflammatory response within
the liver. Interestingly, dietary zinc supplementation
(panel B) significantly attenuated TNFa expression in
the liver such that the relative expression in the liver vs.
the lung decreases from ~35:1 to ~2.5:1. These results
suggest that the chronic and systemic expression of
HIV-1-related proteins, such as occurs during HIV-1
infection, causes a pro-inflammatory response within
the liver, but that the provision of high levels of dietary
zinc somehow mitigates this liver inflammation.
Increased expression of MT1 and ZNT1 in the livers of
HIV-1 transgenic rats suggests zinc sequestration
In the acute phase reaction the liver is known to sequester
zinc. Although our HIV-1 transgenic rat model is not an
infectious model, HIV-1 transgenic rats show signs that
are typical for chronic infections including cachexia and, as
noted above, a dramatic increase in liver-specific expres-
sion of TNFa. Therefore, we examined two indicators of
zinc status in the livers of wild type and HIV-1 transgenic
rats. Metallothionein 1 (MT1) is a cysteine-rich protein
that binds zinc and is usually increased when zinc levels
are high. In parallel, zinc transporters tightly regulate the
movement of zinc across plasma and organellar mem-
branes, and are sensitive indicators of zinc bioavailability at
the cellular level. The solute carrier-39 (SLC39) transporter
family includes a subfamily of ZRT/IRT-related proteins
(ZIPs) that import zinc into the cytosol [28,29]. Another
family of transporters, the solute carrier-30 (SLC30) or
Cation Diffusion Facilitator (CDF) [28,29], include the
ZNT subfamily that export zinc from the cytosol. Zinc
exporters (ZNTs) are up-regulated in cells when zinc levels
are high (to increase export and therefore prevent intracel-
lular zinc toxicity). As shown in Figure 2 (panels A&B),
liver and lung tissues were probed by real-time PCR for
the expression of the zinc storage protein, MT1 and the
zinc exporter, ZNT1. The increase in MT1 and ZNT1 in
the livers of HIV-1 rats was about 39-fold and 11-fold,
Figure 1 HIV-1 transgene expression significantly increases the expression of the pro-inflammatory cytokine, TNFa,i nt h el i v e rb u t
not in the lung, and this pro-inflammatory effect is reversed by dietary zinc supplementation. Panel A shows the relative gene
expression of TNFa in the liver and the lung of wild type and transgenic rats. * p < 0.05 increased compared to liver expression in wild type
rats. Panel B shows the effects of dietary zinc supplementation (100 mg/L) on the ratio of relative TNFa expression in the liver vs. the lung in
HIV-1 transgenic rats. * p < 0.05 decreased compared to untreated HIV-1 transgenic rats (no zinc supplements). In all determinations shown in
Panel A and B, RNA was extracted from the tissues and converted to cDNA. Relative gene expression of TNFa was determined by real-time PCR
using 18S as control and calculated by the ΔΔCT method. Each value represents the mean ± SEM of 4-6 determinations.
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is consistent with hepatic zinc sequestration (i.e. high tissue
zinc levels). Interestingly, dietary zinc supplementation
decreased the liver-specific expression of MT1 and ZNT1,
paralleling its effects on TNFa expression and consistent
with the explanation that the observed inflammation was
causing the liver to sequester zinc. In contrast, the lung-
specific expression of MT1 and ZNT1 was increased after
zinc supplementation, indicating increased zinc bioavail-
ability to the lung. The ratios of the relative gene expres-
sions of MT1 and ZNT1 in the liver vs. the lung are shown
in Figure 2, panel C. Taken together, the data presented in
Figures 1 and 2 suggest that HIV-1-related protein expres-
sion produces a state of chronic liver inflammation that
promotes hepatic zinc sequestration and, as a consequence,
limits zinc bioavailability to other organs such as the lung.
Although as yet unexplained, the provision of high levels of
zinc as a dietary supplement somehow inhibits the aber-
rant expression of TNFa and associated zinc sequestration
in the liver and increases zinc bioavailability in the lungs of
HIV-1 transgenic rats.
HIV-1 transgene expression increased gene expression of
ZIP4 (a zinc importer) and decreased the expression of
ZNT4 (another zinc exporter) in the alveolar
macrophages, and these effects can be reproduced by
treating a macrophage cell line with a zinc chelator in
vitro
As HIV-1 transgene expression significantly lowers zinc
levels in the alveolar space, we next examined its effects
Figure 2 HIV-1 transgene expression alters the gene expression of the zinc storage protein metallothionein-1 (MT1) and the zinc
efflux transporter ZNT1 in the liver and the lung, and these effects are also reversed by dietary zinc supplementation. Panels A&B
show the relative gene expression of MT1 and ZNT1, respectively in the liver and the lung of wild type and transgenic rats. *p < 0.05 increased
compared to liver expression in wild type rats. Panel C shows the effects of dietary zinc supplementation (100 mg/L) on the ratio of relative
gene expression of MT1 and ZNT1 in the liver and the lung of HIV-1 transgenic rats. *p < 0.05 decreased compared to untreated HIV-1
transgenic rats (no zinc supplements). In all determinations shown in Panels A, B and C, RNA was extracted from the tissues and converted to
cDNA. Relative gene expressions of MT1 and ZNT1 were determined by real-time PCR using 18S as control and calculated by the ΔΔCT method.
Each value represents the mean ± SEM of 4-6 determinations.
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macrophages. Data are presented in Figure 3 (panel A)
as the expression of ZIP4 and ZNT4 in HIV-1-derived
macrophages when normalized to the expression of
macrophages from wild type rats. This expression pat-
tern is consistent with a state of zinc deficiency (i.e.,
increase in zinc importers and a decrease in zinc expor-
ters in an effort to preserve intracellular zinc pools).
Further evidence that these changes in ZIP4 and ZNT4
expression reflect zinc deficiency is provided in panel B.
In these experiments, the rat alveolar macrophage cell
line, NR8383 was treated in vitro with or without the
zinc chelator, N,N,N’,N’-tetrakis-(2-pyridyl-methyl) ethy-
lenediamine (TPEN, 5μM) for 24 h, at which time ZIP4
and ZNT4 expression were determined. As is evident in
panel B, acute zinc deficiency induced by TPEN treat-
ment caused changes in ZIP4 and ZNT4 expression that
were comparable to those seen in the alveolar macro-
phages of HIV-1 transgenic rats (panel A).
HIV-1 transgene expression decreased metallothionein
expression and zinc levels in the alveolar macrophage
and these changes can be rapidly reversed with zinc
treatment
As discussed, the zinc storage protein metallothionein is a
good indicator of zinc status in cells and tissues [30]. Since
intracellular zinc levels were significantly decreased in
transgenic rats [9,23], we examined MT1 expression in the
alveolar macrophages from wild type and HIV-1 trans-
genic rats. As predicted, flow cytometric analysis of
alveolar macrophages from HIV-1 transgenic rats showed
a significant decrease in MT1 and zinc positive cells (Fig-
ure 4), which is consistent with our previously reported
findings [23]. Importantly, supplementing the diet with
zinc restored intracellular zinc and MT1 levels (Figure 4).
Dietary zinc supplementation in vivo restores phagocytic
function of alveolar macrophages from HIV-1 transgenic
rats
HIV-1 transgenic rats have significantly decreased intra-
cellular levels of zinc in their alveolar macrophages as
compared to cells from age-matched wild type rats [23].
In this study, no increase in intracellular zinc was
observed in wild type rats after dietary zinc supplemen-
tation. In contrast, HIV-1 transgenic rats whose diets
were supplemented with zinc had significantly higher
intracellular zinc levels in their alveolar macrophages
(Figure 4B), indicating that these cells can indeed import
zinc in vivo if alveolar levels are sufficient. We have pre-
viously determined that alveolar macrophages from
HIV-1 transgenic rats had decreased bacterial phagocy-
tic capacity [23] and this finding was confirmed in the
current study as shown in Figure 5. In contrast, dietary
zinc supplementation not only increased cellular zinc
levels, it also restored bacterial phagocytic capacity in
the alveolar macrophages of HIV-1 transgenic rats (Fig-
ure 5). These new findings extend our previous study in
which we determined that treating alveolar macrophages
f r o mH I V - 1t r a n s g e n i cr a t sw i t hz i n ca c e t a t ein vitro
restored their bacterial phagocytic capacity and raise the
Figure 3 HIV-1 transgene expression, or acute zinc chelation with TPEN, alters gene expression of the zinc transporters ZIP4 and
ZNT4 in alveolar macrophages. Panel A shows the relative expression of ZIP4 and ZNT4 in alveolar macrophages isolated from HIV-1
transgenic rats as compared to alveolar macrophages isolated from wild type rats. Panel B shows the relative expression of ZIP4 and ZNT4 in the
rat alveolar macrophage cell line NR8383 (ATCC) treated with or without the zinc chelator TPEN (5 μM) in vitro for 24 h. In both panels, gene
expression by real time PCR was calculated by the ΔΔCT method and the expression in HIV-1-derived macrophages (Panel A) and TPEN-treated
NR8383 cells (Panel B) were normalized to the expression for macrophages from wild type rats (panel A) and untreated NR8383 cells (panel B).
Each value represents the mean ± SEM of 4 determinations.
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improve alveolar macrophage function in HIV-1-
infected individuals. It is important to note that we did
not identify any effects of dietary zinc supplementation
on alveolar macrophages from wild type rats in terms of
zinc levels (not shown) or in bacterial phagocytic capa-
city (Figure 5). This is consistent with the known
mechanisms by which cellular zinc levels are maintained
in an optimal range by this sensitive transporter system
that senses cellular zinc requirements and regulates the
import and export of zinc in an efficient manner as long
as zinc bioavailability is not limited within the cellular
microenvironment (such as the alveolar space).
Discussion
I nt h i ss t u d yw ed e t e r m i n e dt h a tc h r o n i cH I V - 1t r a n s -
gene expression in rats, which causes a progressive
systemic illness that recapitulates many of the manifes-
tations of AIDS in humans, increases the expression of
the pro-inflammatory cytokine TNFa in the liver but
not in the lung. In parallel, this chronic and systemic
expression of HIV-1-related proteins alters the expres-
sion of zinc transporters and storage proteins within the
liver in a pattern that is consistent with hepatic zinc
sequestration. In contrast, zinc bioavailability in the lung
and the alveolar space is markedly decreased, and alveo-
lar macrophages become zinc-deficient despite altering
their cell-specific expression of zinc transporters in a
pattern that promotes cellular zinc import and reten-
tion. This apparent hepatic zinc sequestration, and con-
sequent relative zinc deficiency within the alveolar
space, has profound consequences on alveolar macro-
phage bacterial phagocytic capacity. In contrast, HIV-1
transgenic rats whose diets were supplemented with
Figure 4 HIV-1 transgene expression decreases metallothionein expression and zinc levels in alveolar macrophages and these
changes can be rapidly reversed with dietary zinc supplementation. Shown are the percentage of alveolar macrophages that were positive
for MT1 (left three columns) and for zinc (right three columns) by flow cytometry performed on macrophages isolated from wild type rats (WT),
from HIV-1 transgenic rats (HIV-1) and from HIV-1 transgenic rats whose drinking water was supplemented with 100 mg/L of zinc acetate (HIV-1
+ zinc). HIV-1 transgenic rats have significantly decreased MT1 expression and intracellular levels of zinc in their alveolar macrophages. Each
value represents the mean ± SEM of 4 determinations. *p < 0.05 decreased compared to untreated wild type rats. **p < 0.05 increased
compared to untreated HIV-1 transgenic rats.
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sequestration and, in parallel, had the same alveolar
macrophage phagocytic function as their wild type litter-
mates. Taken together, these results suggest a novel
mechanism by which chronic HIV infection may cause
alveolar macrophage immune dysfunction and raise the
possibility that dietary zinc supplementation could
enhance pulmonary host defenses in these vulnerable
individuals.
This hypothetical scheme is depicted in Figure 6. We
speculate, based on our previous and current studies,
that the systemic expression of HIV-1-related proteins,
as occurs during chronic HIV-1 infection, promotes
both hepatic inflammation and zinc sequestration. As a
consequence, extrahepatic tissues including the lung
become relatively zinc-deficient, and this has serious
consequences for alveolar macrophage immune func-
tion. Importantly and with potential clinical therapeutic
interventions, dietary zinc supplementation somehow
mitigates these pathophysiological effects in the liver
and restores alveolar macrophage zinc bioavailability
and bacterial phagocytic function. If these experimental
findings ultimately translate to the human condition,
then the relatively simple use of dietary zinc supplemen-
tation could be an effective adjunctive therapy in HIV-
1-infected individuals.
To our knowledge this is the first experimental evi-
dence that systemic expression of HIV-1-related pro-
t e i n sc a u s e st h e s ed i f f e r e n tial effects on inflammation
and zinc bioavailability in the liver vs. the lung. There-
f o r e ,w eb e l i e v et h e s ef i n d i n g sa r ep r o v o c a t i v ei nt h a t
they provide a novel mechanism by which chronic HIV-
1 infection could impair innate immunity within the
lower airways. However, there are some limitations to
this initial study that will require future studies to
address. Specifically, it is as yet unknown how these
HIV-1-related proteins promote TNFa expression
within the liver and not in the lung. Perhaps even more
important to determine is how dietary zinc supplemen-
tation mitigates liver-specific inflammation and apparent
zinc sequestration. As zinc is a cofactor for more than
300 enzymes and is critical to the function of thousands
Figure 5 Dietary zinc supplementation in HIV-1 transgenic rats increases the bacterial phagocytic capacity of alveolar macrophages.
The bacterial phagocytic capacity (as reflected by phagocytic indices) of alveolar macrophages from wild type and HIV-1 transgenic rats were
determined by flow cytometry as described in Materials and Methods. Each value represents the mean ± SEM of 4-6 rats in each group. *p <
0.05 decreased compared to untreated wild type rats. **p < 0.05 increased compared to untreated HIV-1 transgenic rats.
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likely attributable to more than one specific effect.
Further, the salutary effects of dietary zinc supplementa-
tion on alveolar macrophage zinc bioavailability and
phagocytic function may not occur independently of, or
in spite of, the HIV-1-induced liver inflammation and
zinc sequestration, as zinc corrects both the liver and
lung abnormalities. Therefore, the provision of dietary
zinc supplements (at levels that are many times higher
than could possibly be contained in even the ‘healthiest’
of diets), somehow mitigates the liver inflammation and
zinc sequestration and may thereby make zinc available
to extrahepatic tissues including the lung. Specifically, if
dietary zinc supplements were simply bypassing the liver
and replenishing the lung’s supply, this might explain
the beneficial effects on alveolar macrophage function
but would not explain the remarkable reversal of liver-
specific TNFa expression and the associated changes in
zinc storage and transport proteins that suggest hepatic
zinc sequestration.
Despite improvements in HIV-1 treatment there are
compelling reasons to identify and test such adjunctive
treatments, as pulmonary infections and respiratory fail-
ure remain significant challenges even in the era of anti-
retroviral therapy and are associated with high rates of
morbidity and mortality. Therefore, although the overall
prognosis has greatly improved it remains critically
important to understand how HIV-1 renders the lung
susceptible to infection and injury. Evidence continues
to evolve implicating HIV-1-related proteins, including
gp120 and Tat, as mediators of oxidant stress and injury
even in target cells that are not directly infected with
the virus. We had previously reported that this may be
due in part to a significant decrease in the levels of the
antioxidant glutathione in the alveolar space [27].
Further, we have identified that these proteins cause sig-
nificant zinc deficiency within the lung, and zinc is
essential for both immune and anti-oxidant defenses.
This may be particularly relevant during chronic malnu-
trition where glutathione and zinc decrease during star-
vation or protein-deficiency [30-33]. However, in our
study rats were pair-fed a protein-sufficient diet and
there were no significant differences in the consumption
of diet between wild type and transgenic rats. Therefore,
it is plausible to speculate that chronic expression and
circulation of HIV-1-related proteins causes liver inflam-
mation (as reflected by high TNFa expression) and
malaise. The liver is the primary source of glutathione
synthesis and storage in the body and, as zinc is known
to restore glutathione levels in cells [34], it is possible
that dietary zinc supplementation decreased liver inflam-
mation in HIV-1 transgenic rats at least in part by aug-
menting glutathione levels in the liver. Regardless of the
specific mechanism(s) involved, the effects of dietary
zinc supplementation on hepatic TNFa expression were
remarkable. Further, the down-modulation of hepatic
inflammation reversed the changes in the expression of
zinc storage and transport proteins that promote zinc
sequestration and restored zinc bioavailability and pha-
gocytic function to the alveolar macrophage. Although
Figure 6 Proposed hypothetical scheme: HIV-1 transgene and proteins cause hepatic inflammation and hepatic zinc sequestration
resulting in pulmonary zinc deficiency, and decreased alveolar macrophage function. Dietary zinc supplementation modulates this vicious
cycle and reduces pulmonary effects mediated by HIV-1 transgene and related proteins.
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Page 9 of 11the underlying mechanisms will need to be dissected,
these findings provide intriguing evidence that HIV-1-
related proteins can impact lung host immunity by an
unexpected effect on hepatic inflammation and zinc
sequestration. In this context, our current findings also
complement our previous studies in which we deter-
mined that HIV-1 transgene expression causes oxidative
stress, glutathione depletion, and alveolar epithelial bar-
rier dysfunction [27].
These effects on alveolar host defenses and the epithe-
lium are clinically relevant, as a robust response to
environmental challenges including microbial invasion
of the lower airways requires coordinated defenses
involving the alveolar epithelial barrier and the resident
alveolar macrophage. We have taken advantage of this
novel HIV-1 transgenic rat model, in which HIV-1-
related proteins are expressed and the animal develops
an impressive AIDS-like phenotype in the absence of
viral infection/replication, to study the effects of these
proteins on alveolar macrophage and epithelial function.
Although anti-retroviral therapy can control viral repli-
cation in most cases, the HIV-1 related proteins still cir-
culate [35] and can have adverse effects on cellular
function. The data presented here suggest that supple-
menting anti-retroviral therapy with dietary zinc could
be beneficial to pulmonary host immune responses.
Further, such a complementary therapy could also bene-
f i tH I V - i n f e c t e dp a t i e n t sw i t hc o - m o r b i dc o n d i t i o n s
such as alcohol abuse, as we recently determined that
dietary zinc supplementation also improves alveolar
macrophage function in alcohol-fed rats [36].
Conclusion
In summary, we report that HIV-1 transgene expression,
and therefore the chronic expression and systemic circu-
lation of HIV-1-related proteins, induces an acute phase-
like response resulting in a differential expression of
TNFa in the liver as compared to the lung. In parallel,
alterations in the expression of zinc storage and transport
proteins suggest zinc sequestration in the liver and as a
consequence, zinc deprivation and alveolar macrophage
dysfunction in the lung. In contrast, dietary zinc supple-
mentation decreases TNFa expression and apparent zinc
sequestration in the liver, replenishes intracellular levels
of zinc in the alveolar macrophages, and improves alveo-
lar macrophage bacterial phagocytic function.
Additional material
Additional file 1: Body weights of wild type and HIV-1 transgenic
rats. Panel A shows representative pictures of these rats in each group;
of particular note are the smaller body size and the scruffy coat in the
HIV-1 transgenic rat compared to its wild type littermate. Panel B shows
the body weights of 9 month old wild type (WT) and HIV-1 transgenic
(HIV-1-Tg) littermate rats; each value represents the mean ± SEM of 6
rats. * p < 0.05 decreased body weights compared to wild type
littermates.
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